Jim Simons Idera Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.23 - $0.43 $92 - $172	400 Added 1.28%	31,700 $11,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.53 $76 - $106	-200 Reduced 0.63%	31,300 $12,000
Q2 2022 Aug 12, 2022	BUY	$0.32 - $0.74 $10,080 - $23,310	31,500 New	31,500 $14,000
Q4 2021 Feb 11, 2022	SELL	$0.53 - $1.03 $143,969 - $279,789	-271,640 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.0 - $1.18 $271,640 - $320,535	271,640 New	271,640 $280,000
Q2 2021 Aug 13, 2021	SELL	$1.01 - $1.58 $126,344 - $197,648	-125,094 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$1.23 - $5.98 $1.09 Million - $5.31 Million	-888,055 Reduced 87.65%	125,094 $163,000
Q4 2020 Feb 10, 2021	BUY	$2.09 - $5.18 $111,854 - $277,228	53,519 Added 5.58%	1,013,149 $3.72 Million
Q3 2020 Nov 13, 2020	SELL	$1.71 - $2.68 $123,662 - $193,809	-72,317 Reduced 7.01%	959,630 $2.05 Million
Q2 2020 Aug 13, 2020	BUY	$1.23 - $2.12 $516,351 - $889,971	419,798 Added 68.58%	1,031,947 $1.85 Million
Q1 2020 May 14, 2020	BUY	$1.06 - $2.15 $71,138 - $144,290	67,112 Added 12.31%	612,149 $808,000
Q4 2019 Feb 13, 2020	BUY	$1.45 - $2.79 $300,167 - $577,563	207,012 Added 61.24%	545,037 $992,000
Q3 2019 Nov 13, 2019	BUY	$2.12 - $3.31 $92,008 - $143,654	43,400 Added 14.73%	338,025 $977,000
Q2 2019 Aug 12, 2019	BUY	$2.37 - $3.97 $98,295 - $164,655	41,475 Added 16.38%	294,625 $787,000
Q1 2019 May 14, 2019	BUY	$2.33 - $3.79 $452,924 - $736,730	194,388 Added 330.81%	253,150 $646,000
Q4 2018 Feb 13, 2019	BUY	$2.77 - $9.38 $162,770 - $551,187	58,762 New	58,762 $163,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.